IP Library Granted Patent US 11,459,305
Granted Patent B2
US 11,459,305 · App. 16/739,263 · Granted Oct 4, 2022

Processes for the preparation of uracil derivatives

Inventors: Donald J. Gallagher (Hopkinton, MA); Laszlo R. Treiber (San Diego, CA); Robert Michael Hughes (San Diego, CA); Onorato Campopiano (Hayward, CA); Peng Wang (Carlsbad, CA); Yuxin Zhao (San Diego, CA); Shine K. Chou (Wildwood, MO); Michael Allen Ouellette (San Diego, CA); Donald Nicholas Hettinger (Broomfield, CO)
Assignee: Neurocrine Biosciences, Inc.
C07D239/54A61P15/00C07D239/553A61K9/146A61K9/1688
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,459,305
App. No.
16/739,263
Granted
Oct 4, 2022
Kind
B2
Abstract

The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.

Claims (13)

1. A formulation comprising a spray-dried amorphous co-solution of a compound of formula 5-1

and an excipient or other carrier.

2. The formulation of claim 1 , wherein the excipient or other carrier is mannitol, polyvinyl pyrrolidone and/or hydroxypropylmethylcellulose.

3. A method for treating a condition selected from prostate cancer, breast cancer, endometriosis, uterine leiomyoma (fibroids), ovarian cancer, prostatic hyperplasia, assisted reproductive therapy, and precocious puberty in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the formulation of claim 1 .

4. The method of claim 3 , wherein the condition is endometriosis.

5. The method of claim 3 , wherein the condition is uterine leiomyoma (fibroids).

6. A formulation comprising an amorphous co-solution of a compound of formula 5-1

and an excipient or other carrier.

7. The formulation of claim 6 , wherein the excipient or other carrier is a polymer.

8. The formulation of claim 6 , wherein the excipient or other carrier is selected from mannitol, polyvinyl pyrrolidone and hydroxypropylmethylcellulose.

9. A method for treating a condition selected from prostate cancer, breast cancer, endometriosis, uterine leiomyoma (fibroids), ovarian cancer, prostatic hyperplasia, assisted reproductive therapy, and precocious puberty in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the formulation of claim 6 .

10. The method of claim 9 , wherein the condition is endometriosis.

11. The method of claim 9 , wherein the condition is uterine leiomyoma (fibroids).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2022
From: GALLAGHER, DONALD J; TREIBER, LASZLO R; HUGHES, ROBERT MICHAEL; CAMPOPIANO, ONORATO; WANG, PENG; ZHAO, YUXIN; CHOU, HELEN; OUELLETTE, MICHAEL ALLEN; HETTINGER, DONALD NICHOLAS
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 060926/0848 →
Continuity (8)
Continuation 16020814 · Jun 27, 2018
Continuation 15833513 · Dec 6, 2017
Continuation 15406476 · Jan 13, 2017
Continuation 15174774 · Jun 6, 2016
Continuation 14309732 · Jun 19, 2014
Division 12741819
Provisional Application 60986227 · Nov 7, 2007
Related Publication 20200255387A1 · Aug 13, 2020